Výnosy R/R společnosti Kazia Therapeutics
Jaká je hodnota metriky Výnosy R/R společnosti Kazia Therapeutics?
Hodnota metriky Výnosy R/R společnosti Kazia Therapeutics Limited je N/A
Jaká je definice metriky Výnosy R/R?
Čtvrtletní růst výnosů (Revenue Q / Q) z roku na rok je nárůst příjmů firmy ve srovnání s výsledky v korespondujícího čtvrtletí minulého roku vyjádřeného v procentech.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Čemu se věnuje společnost Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.